Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1977 Nov;61(3):357–369. doi: 10.1111/j.1476-5381.1977.tb08428.x

BRL 13776: a novel antihypertensive agent with interesting monoamine depleting properties.

J Melrose, M G Palfreyman, R H Poyser, R L Whiting
PMCID: PMC1667860  PMID: 588803

Abstract

1. Oral doses of 10-100 mg/kg of BRL 13776 lowered the blood pressure of both deoxycorticosterone acetate (DOCA)/NaCl-treated hypertensive rats and untreated normotensive rats. 2. BRL 13776 (100 mg/kg, orally) also reduced the blood pressure of renal hypertensive cats (cellophane perinephritis model). 3. No tolerance developed to the blood-pressure lowering action of BRL 13776 when an oral daily dose of 100 mg/kg was administered repeatedly for up to 15 days to hypertensive rats and cats. 4. The fall in blood pressure to BRL 13776 in rats was associated with a reduction of tissue catecholamines. 5. The catecholamine depletion occurred in all the peripheral tissues examined but in the brain was restricted to certain regions, these being the hind-brain on single dosing and the hind-brain, hypothalamus and mid-brain on repeated dosing. Catecholamine levels in the cerebral hemispheres were not affected by either single or repeated doses of BRL 13776. 6. BRL 13776 caused some reduction of the 5-hydroxytryptamine content of the heart but not of whole brain or any brain region. 7. Neither single doses (up to 900 mg/kg orally) nor repeated doses (100-300 mg/kg orally) of BRL 13776 produced any significant behavioural effects in animals. 8. BRL 13776 is a new type of agent to display both antihypertensive and monoamine-depleting properties. The reduction of noradrenaline in certain brain regions may be a cause of the antihypertensive response but depletion in the periphery could contribute in a major or minor way. The differential action on noradrenaline in the brain together with the lack of effect on 5-hydroxytryptamine might also explain the apparent absence of behavioural effects.

Full text

PDF
357

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bensemana D., Gascon A. L. Effect of delta9THC on the distribution uptake and release of catecholamine in rats. Rev Can Biol. 1974 Dec;33(4):269–278. [PubMed] [Google Scholar]
  2. Birmingham M. K. Reduction by 9-tetrahydrocannabinol in the blood pressure of hypertensive rats bearing regenerated adrenal glands. Br J Pharmacol. 1973 May;48(1):169–171. doi: 10.1111/j.1476-5381.1973.tb08236.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bracs P., Jackson D. M., Chesher G. B. The effect of delta9-tetrahydrocannabinol on brain amine concentration and turnover in whole rat brain and in various regions of the brain. J Pharm Pharmacol. 1975 Sep;27(9):713–715. doi: 10.1111/j.2042-7158.1975.tb09541.x. [DOI] [PubMed] [Google Scholar]
  4. Chalmers J. P. Brain amines and models of experimental hypertension. Circ Res. 1975 Apr;36(4):469–480. doi: 10.1161/01.res.36.4.469. [DOI] [PubMed] [Google Scholar]
  5. Day M. D., Whiting R. L. An improved technique for the continuous measurement of arterial blood pressure in the conscious unrestrained cat. Br J Pharmacol. 1972 May;45(1):182P–182P. [PMC free article] [PubMed] [Google Scholar]
  6. GOODMAN L. S., GREWAL M. S., BROWN W. C., SWINYARD E. A. Comparison of maximal seizures evoked by pentylenetetrazol (metrazol) and electroshock in mice, and their modification by anticonvulsants. J Pharmacol Exp Ther. 1953 Jun;108(2):168–176. [PubMed] [Google Scholar]
  7. Glowinski J., Iversen L. L. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem. 1966 Aug;13(8):655–669. doi: 10.1111/j.1471-4159.1966.tb09873.x. [DOI] [PubMed] [Google Scholar]
  8. Graham J. D., Lewis M. J., Li D. M. The effect of delta1-tetrahydrocannabinol on the release of (3H-(-)-noradrenaline from the isolated vas deferens of the rat. Br J Pharmacol. 1974 Oct;52(2):233–236. doi: 10.1111/j.1476-5381.1974.tb09705.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Haeusler G. Cardiovascular regulation by central adrenergic mechanisms and its alteration by hypotensive drugs. Circ Res. 1975 Jun;36(6 Suppl 1):223–232. doi: 10.1161/01.res.36.6.223. [DOI] [PubMed] [Google Scholar]
  10. Ho B. T., Taylor D., Englert L. F., McIsaac W. M. Neurochemical effects of L-tetra 9-tetrahydrocannabinol in rats following repeated inhalation. Brain Res. 1971 Aug 7;31(1):233–236. doi: 10.1016/0006-8993(71)90652-4. [DOI] [PubMed] [Google Scholar]
  11. Holtzman D., Lovell R. A., Jaffe J. H., Freedman D. X. 1-delta9-tetrahydrocannabinol: neurochemical and behavioral effects in the mouse. Science. 1969 Mar 28;163(3874):1464–1467. doi: 10.1126/science.163.3874.1464. [DOI] [PubMed] [Google Scholar]
  12. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia. 1968 Sep 20;13(3):222–257. doi: 10.1007/BF00401402. [DOI] [PubMed] [Google Scholar]
  13. LEROY J. G., DE SCHAEPDRYVER A. F. Catecholamine levels of brain and heart in mice after iproniazid, syrosingopine and 10-methoxydeserpidine. Arch Int Pharmacodyn Ther. 1961 Feb 1;130:231–234. [PubMed] [Google Scholar]
  14. Maître L., Staehelin M., Bein H. J. Effect of an extract of cannabis and of some cannabinols on catecholamine metabolism in rat brain and heart. Agents Actions. 1970 Mar;1(3):136–143. doi: 10.1007/BF01982400. [DOI] [PubMed] [Google Scholar]
  15. Melrose J., Palfreyman M. G., Poyser R. H., Whiting R. L. Proceedings: BRL 13776: a novel antihypertensive agent with interesting noradrenaline-depleting properties. Br J Pharmacol. 1976 Mar;56(3):361P–361P. [PMC free article] [PubMed] [Google Scholar]
  16. Morpurgo C. Aggressive behavior induced by large doses of 2-(2,6-dichlorphenylamino)-2-imidazoline hydrochloride (ST 155) in mice. Eur J Pharmacol. 1968 Jul;3(4):374–377. doi: 10.1016/0014-2999(68)90126-x. [DOI] [PubMed] [Google Scholar]
  17. Nahas G. G., Schwartz I. W., Adamec J., Manger W. M. Tolerance of delta-9-tetrahydrocannabinol in the spontaneously hypertensive rat. Proc Soc Exp Biol Med. 1973 Jan;142(1):58–60. doi: 10.3181/00379727-142-36957. [DOI] [PubMed] [Google Scholar]
  18. Nakamura K., Gerold M., Thoenen H. Experimental hypertension of the rat: reciprocal changes of norepinephrine turnover in heart and brain-stem. Naunyn Schmiedebergs Arch Pharmakol. 1971;268(2):125–139. doi: 10.1007/BF01020067. [DOI] [PubMed] [Google Scholar]
  19. ORLANS F. B., FINGER K. F., BRODIE B. B. Pharmacological consequences of the selective release of peripheral norepinephrine by syrosingopine (Su 3118). J Pharmacol Exp Ther. 1960 Feb;128:131–139. [PubMed] [Google Scholar]
  20. Pham-Huu-Chanh, De Schaepdryver A. F. On the pharmacology of syrosingopine and reserpine. Arch Int Pharmacodyn Ther. 1965 Sep;157(1):207–213. [PubMed] [Google Scholar]
  21. Poyser R. H., Shorter J. H., Whiting R. L. Proceedings: The production of hypertension and the effects of some antihypertensive agents in the conscious unrestrained cat. Br J Pharmacol. 1974 May;51(1):149P–149P. [PMC free article] [PubMed] [Google Scholar]
  22. SWINYARD E. A., BROWN W. C., GOODMAN L. S. Comparative assays of antiepileptic drugs in mice and rats. J Pharmacol Exp Ther. 1952 Nov;106(3):319–330. [PubMed] [Google Scholar]
  23. Schildkraut J. J., Efron D. H. The effects of delta-9-tetrahydrocannabinol on the metabolism of norepinephrine in rat brain. Psychopharmacologia. 1971;20(2):191–196. doi: 10.1007/BF00404373. [DOI] [PubMed] [Google Scholar]
  24. Shellenberger M. K., Gordon J. H. A rapid, simplified procedure for simultaneous assay of norepinephrine, dopamine, and 5-hydroxytryptamine from discrete brain areas. Anal Biochem. 1971 Feb;39(2):356–372. doi: 10.1016/0003-2697(71)90426-x. [DOI] [PubMed] [Google Scholar]
  25. Snyder S. H., Axelrod J., Zweig M. A sensitive and specific fluorescence assay for tissue serotonin. Biochem Pharmacol. 1965 May;14(5):831–835. doi: 10.1016/0006-2952(65)90102-4. [DOI] [PubMed] [Google Scholar]
  26. Varma D. R., Goldbaum D. Effect of delta9-tetrahydrocannabinol on experimental hypertension in rats. J Pharm Pharmacol. 1975 Oct;27(10):790–791. doi: 10.1111/j.2042-7158.1975.tb09406.x. [DOI] [PubMed] [Google Scholar]
  27. Williams R. B., Ng L. K., Lamprecht F., Roth K., Kopin I. J. 9 -Tetrahydrocannabinol: a hypotensive effect in rats. Psychopharmacologia. 1973;28(3):269–274. doi: 10.1007/BF00429307. [DOI] [PubMed] [Google Scholar]
  28. Yagiela J. A., McCarthy K. D., Gibb J. W. The effect of hypothermic doses of 1-delta 9-tetrahydrocannabinol on biogenic amine metabolism in selected parts of the rat brain. Life Sci. 1974 Jun 16;14(12):2367–2378. doi: 10.1016/0024-3205(74)90132-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES